Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
Adult
Aged
Aged, 80 and over
Bevacizumab
/ administration & dosage
Cell Proliferation
/ drug effects
Colorectal Neoplasms
/ drug therapy
Combined Modality Therapy
Disease-Free Survival
Female
Hepatectomy
/ methods
Humans
Liver Neoplasms
/ drug therapy
Male
Middle Aged
Neoadjuvant Therapy
/ methods
Neoplasm Metastasis
Neoplasm Recurrence, Local
/ drug therapy
Phenotype
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
02
12
2019
accepted:
03
03
2020
revised:
18
02
2020
pubmed:
25
3
2020
medline:
23
12
2020
entrez:
25
3
2020
Statut:
ppublish
Résumé
Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection. CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated. One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0-80.4) years, median follow-up 32.2 (5.0-92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60, P = 0.001) and OS (36.6 months versus not reached, HR 2.32, P = 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85, P = 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS. The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture.
Sections du résumé
BACKGROUND
Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection.
METHODS
CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated.
RESULTS
One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0-80.4) years, median follow-up 32.2 (5.0-92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60, P = 0.001) and OS (36.6 months versus not reached, HR 2.32, P = 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85, P = 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS.
CONCLUSIONS
The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture.
Identifiants
pubmed: 32205863
doi: 10.1038/s41416-020-0812-z
pii: 10.1038/s41416-020-0812-z
pmc: PMC7217855
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1518-1524Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung)
ID : J3501-B13
Pays : International
Références
Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27, 3677–3683 (2009).
doi: 10.1200/JCO.2008.20.5278
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P. et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14, 1208–1215 (2013).
doi: 10.1016/S1470-2045(13)70447-9
Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C., Herbst, F. et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J. Clin. Oncol. 26, 1830–1835 (2008).
doi: 10.1200/JCO.2007.13.7679
Cui, C. H., Huang, S. X., Qi, J., Zhu, H. J., Huang, Z. H. & Yu, J. L. Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: a systematic review and meta-analysis. Oncotarget 6, 44005–44018 (2015).
pubmed: 26515604
pmcid: 4791282
Klinger, M., Tamandl, D., Eipeldauer, S., Hacker, S., Herberger, B., Kaczirek, K. et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann. Surg. Oncol. 17, 2059–2065 (2010).
doi: 10.1245/s10434-010-0972-9
Vermeulen, P. B., Colpaert, C., Salgado, R., Royers, R., Hellemans, H., Van Den Heuvel, E. et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 195, 336–342 (2001).
doi: 10.1002/path.966
van Dam, P. J., van der Stok, E. P., Teuwen, L. A., Van den Eynden, G. G., Illemann, M., Frentzas, S. et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br. J. Cancer 117, 1427–1441 (2017).
doi: 10.1038/bjc.2017.334
Donnem, T., Reynolds, A. R., Kuczynski, E. A., Gatter, K., Vermeulen, P. B., Kerbel, R. S. et al. Non-angiogenic tumours and their influence on cancer biology. Nat. Rev. Cancer 18, 323–336 (2018).
doi: 10.1038/nrc.2018.14
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E. et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat. Med. 22, 1294–1302 (2016).
doi: 10.1038/nm.4197
Barnhill, R., Vermeulen, P., Daelemans, S., van Dam, P. J., Roman-Roman, S., Servois, V. et al. Replacement and desmoplastic histopathological growth patterns: a pilot study of prediction of outcome in patients with uveal melanoma liver metastases. J. Pathol. Clin. Res. https://doi.org/10.1002/cjp2.105 (2018).
Kuczynski, E. A., Yin, M., Bar-Zion, A., Lee, C. R., Butz, H., Man, S. et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djw030 (2016).
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
doi: 10.1038/nature21349
Brunner, S. M., Kesselring, R., Rubner, C., Martin, M., Jeiter, T., Boerner, T. et al. Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br. J. Surg. 101, 1681–1691 (2014).
doi: 10.1002/bjs.9627
Halama, N., Michel, S., Kloor, M., Zoernig, I., Pommerencke, T., von Knebel Doeberitz, M. et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 9, 1 (2009).
pubmed: 19226101
pmcid: 2935770
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
Rubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A. D., Andres, A., Audard, V. et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann. Oncol. 18, 299–304 (2007).
doi: 10.1093/annonc/mdl386
Pogue-Geile, K., Yothers, G., Taniyama, Y., Tanaka, N., Gavin, P., Colangelo, L. et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J. Natl Cancer Inst. 105, 989–992 (2013).
doi: 10.1093/jnci/djt140
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S. et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
doi: 10.1038/ncomms12624
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632–642 (2014).
doi: 10.1158/2326-6066.CIR-14-0053
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
doi: 10.1056/NEJMoa1500596
Stessels, F., Van den Eynden, G., Van der Auwera, I., Salgado, R., Van den Heuvel, E., Harris, A. L. et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br. J. Cancer 90, 1429–1436 (2004).
doi: 10.1038/sj.bjc.6601727
Van den Eynden, G. G., Bird, N. C., Majeed, A. W., Van Laere, S., Dirix, L. Y. & Vermeulen, P. B. The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin. Exp. Metastasis 29, 541–549 (2012).
doi: 10.1007/s10585-012-9469-1
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
doi: 10.1126/science.1104819
Stremitzer, S., Zhang, W., Yang, D., Ning, Y., Stintzing, S., Sebio, A. et al. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer 121, 1898–1905 (2015).
doi: 10.1002/cncr.29259
van Dam, P. J., Daelemans, S., Ross, E., Waumans, Y., Van Laere, S., Latacz, E. et al. Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. Semin. Cancer Biol. 52(Pt 2), 86–93 (2018).
pubmed: 29355613